OTC : ARSUF
$0 (0.0%)
OTC
Rafael Padilla
Drug Manufacturers - Specialty & Generic
Healthcare
ARSUF
3828
BE
USD
0.85
2.11
1.39
0.84
0.29
$951.81M
1.83
3.15
13.37
1.78
$1.24
$90.99M
9.56%
12.35%
17.29%
7.32%
19.15
1.50
1.50
4/5
0 Analysts
%
3.87
7/9
$243.77M
$1.24B
$686.62M
$269.33M
$2.03B
2.13
10.95
2.11
17.29%
11.09%
5.24%
7.48%
$14.52
53 days
| Name | Title |
|---|---|
| Ignacio Artola | Global Head of Investor Relations |
| Rafael Padilla | Chief Executive Officer & Executive Director |
| Karin de Jong | Chief Financial Officer & Executive Director |
| Vera Bakker | Chief Operating Officer |
No votes yet today — be the first to share your view!
About Fagron N.V. (OTC:ARSUF) Stock
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. W ... ith a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.
Fagron shareholders approve all proposed resolutions at the General Meetings
2026-05-11 12:00:00
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 May 2026 – 6PM CET Fagron shareholders approve all proposed resolutions at the General Meetings Fagron, the leading global player in pharmaceutical compounding, today held its Annual and Extraordinary General Meeting of Shareholders. All resolutions proposed by the Board of Directors were approved.
Frequently Asked Questions
What is the current Fagron N.V. (ARSUF) stock price?
Fagron N.V.(OTC:ARSUF) stock price is $26.53 in the last trading session. During the trading session, ARSUF stock reached the peak price of $27 while $23.5 was the lowest point it dropped to. The percentage change in ARSUF stock occurred in the recent session was 0.0% while the dollar amount for the price change in ARSUF stock was $0.
ARSUF's industry and sector of operation?
The OTC listed ARSUF is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
Who are the executives of ARSUF?
Ignacio Artola
| Global Head of Investor Relations
Rafael Padilla
| Chief Executive Officer & Executive Director
Karin de Jong
| Chief Financial Officer & Executive Director
Vera Bakker
| Chief Operating Officer
|
How many employees does ARSUF have?
Number of ARSUF employees currently stands at 3828. ARSUF operates from Venecoweg 20A, Nazareth, VL 9810, BE.
Link for ARSUF official website?
Official Website of ARSUF is: https://www.fagron.com
How do I contact ARSUF?
ARSUF could be contacted at phone #32 8 001 28 80 and can also be accessed through its website. ARSUF operates from Venecoweg 20A, Nazareth, VL 9810, BE.
How many shares of ARSUF are traded daily?
The average number of ARSUF shares traded daily for last 3 months was 2.59K.
What is the market cap of ARSUF currently?
The market value of ARSUF currently stands at $1.95B with its latest stock price at $26.53